0001437749-23-028705.txt : 20231023
0001437749-23-028705.hdr.sgml : 20231023
20231023060802
ACCESSION NUMBER: 0001437749-23-028705
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231020
FILED AS OF DATE: 20231023
DATE AS OF CHANGE: 20231023
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rafael Holdings, Inc.
CENTRAL INDEX KEY: 0001713863
STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE [6500]
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0731
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39780
FILM NUMBER: 231338449
BUSINESS ADDRESS:
STREET 1: 520 BROAD STREET
CITY: NEWARK
STATE: NJ
ZIP: 07120
BUSINESS PHONE: 212-658-1450
MAIL ADDRESS:
STREET 1: 520 BROAD STREET
CITY: NEWARK
STATE: NJ
ZIP: 07120
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cyclo Therapeutics, Inc.
CENTRAL INDEX KEY: 0000922247
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 593029743
STATE OF INCORPORATION: FL
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6714 NW 16TH STREET, SUITE B
CITY: GAINESVILLE
STATE: FL
ZIP: 32653
BUSINESS PHONE: 386-418-8060
MAIL ADDRESS:
STREET 1: PO BOX 1180
CITY: ALACHUA
STATE: FL
ZIP: 32616-1180
FORMER COMPANY:
FORMER CONFORMED NAME: CTD HOLDINGS INC
DATE OF NAME CHANGE: 20000913
FORMER COMPANY:
FORMER CONFORMED NAME: CYCLODEXTRIN TECHNOLOGIES DEVELOPMENT INC
DATE OF NAME CHANGE: 19941012
4
1
rdgdoc.xml
FORM 4
X0508
4
2023-10-20
0000922247
Cyclo Therapeutics, Inc.
CYTH
0001713863
Rafael Holdings, Inc.
520 BROAD STREET
NEWARK
NJ
07055
1
0
Common Stock
2023-10-20
4
X
0
2514970
0.71
A
9029940
D
Warrant to Purchase Common Stock
0.71
2023-10-20
4
X
0
2514970
0.125
D
2023-07-31
2030-07-31
Common Stock
2514970
0
D
Warrant to Purchase Common Stock
0.95
2023-10-20
4
P
0
2766467
A
2023-10-20
2027-10-20
Common Stock
2766467
2766467
D
The Reporting Person exercised vested Warrants (the "Original Warrants") to purchase 2,514,970 shares of the Issuer's common stock pursuant to a Securities Purchase Agreement dated October 20, 2023 ("Closing Date"). The Reporting Person exercised its Original Warrant in full on or prior to the Closing Date in consideration of the receipt of new warrants with an exercise price equal to $0.95 per share, to purchase 110% of the shares of the Issuer's common stock covered under the Original Warrants.
/s/ William Conkling, CEO
2023-10-23